title: Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
abstract: BACKGROUND
  The aim of this study was to examine nuclear p53 overexpression in transitional cell carcinoma of the bladder, adenocarcinoma of the prostate, and renal cell carcinoma.
  
  
  METHODS
  Forty-four pathologic specimens from 39 bladder cancer patients, 41 prostatic adenocarcinoma, and 39 renal cell carcinoma specimens were analyzed immunohistochemically with D07 monoclonal antibody to detect the expression of the mutant p53 gene. Overexpression was said to occur when the number of positively-stained tumor nuclei were > or = 10% in each specimen. p53 overexpression was correlated with the clinical and histopathological features of these cancers.
  
  
  RESULTS
  Nuclear p53 overexpression occurred in 18.2% of transitional cell bladder cancer specimens, 12.2% of prostate cancer specimens, and 17.9% of renal cell cancer specimens. Statistical analyses showed that grade, vascular invasion, and necrosis in bladder cancer, a high Gleason score in prostate cancer, and the 1-year mortality rate in renal cancer were significantly related with p53 nuclear overexpression (P < 0.05).
  
  
  CONCLUSIONS
  Using the D07 monoclonal antibody, nuclear p53 overexpression is relatively uncommon in urologic malignancies, and moderately correlates with several histopathological and clinical features of urologic malignancies.
authors.affiliation: Department of Urology, School of Medicine, Gazi University, Ankara, Turkey.
authors.forename: Z
authors.initials: Z
authors.lastname: Sinik
authors.forename: T
authors.initials: T
authors.lastname: Alkibay
authors.forename: O
authors.initials: O
authors.lastname: Ataoglu
authors.forename: H
authors.initials: H
authors.lastname: Biri
authors.forename: S
authors.initials: S
authors.lastname: Sözen
authors.forename: N
authors.initials: N
authors.lastname: Deniz
authors.forename: U
authors.initials: U
authors.lastname: Karaoglan
authors.forename: I
authors.initials: I
authors.lastname: Bozkirli
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000368:Aged; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000473:pathology; D005500:Follow-Up Studies; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53